In this episode of The Dales Report, Shadd Dales is joined by Professor David Nutt (CRO) and Anthony Tennyson (CEO) of Awakn Life Sciences. They discuss the recent announcement of positive data from Awakn clinical trials on ketamine-assisted therapy for alcohol use disorder and more about addiction and the brain.
Category Popular Press
Scientific / Research
Published in The Dales Report
Companies Featured
Awakn Life SciencesAWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.